Literature DB >> 18569396

Interactions between B-lymphocytes and type 1 NKT cells in autoimmune diabetes.

François D Dufour1, Pablo A Silveira, Alan G Baxter.   

Abstract

Type 1 diabetes is one of the most prevalent autoimmune conditions that develops during childhood and has an increasing incidence worldwide. The disease results from the destruction of pancreatic beta cells mediated by autoreactive T-lymphocytes. In order to develop preventive therapies, the cellular mechanisms responsible for the generation and activation of beta cell-specific T-lymphocytes need to be characterized. Recent studies in the NOD mouse model of autoimmune diabetes suggest that the MHC Class II presentation of beta cell-derived antigens by B-lymphocytes could support the development and activity of autoreactive CD4+ T-lymphocytes in this disease. Interestingly, B-lymphocytes are also the most frequent antigen presenting cells expressing the MHC Class I like molecule, CD1d, the restriction molecule responsible for presentation of lipid and glycolipid antigens to Type 1 NKT cells. Splenic marginal zone B-lymphocytes, which express CD1d at particularly high levels, seem poised to signal to Type 1 NKT cells. In contrast to the disease-promoting role of conventional CD4+ T-lymphocytes, several lines of evidence have shown that Type 1 NKT cells are involved in the prevention of Type 1 Diabetes. This review will analyze current knowledge on the roles of B-lymphocytes and Type 1 NKT cells in the onset of Type 1 Diabetes and explore possible outcomes of their interactions in relation to disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18569396     DOI: 10.1080/15476910802131543

Source DB:  PubMed          Journal:  J Immunotoxicol        ISSN: 1547-691X            Impact factor:   3.000


  3 in total

1.  CD1a and CD1d genes polymorphisms in breast, colorectal and lung cancers.

Authors:  Hossein Golmoghaddam; Abdul Mohammad Pezeshki; Abbas Ghaderi; Mehrnoosh Doroudchi
Journal:  Pathol Oncol Res       Date:  2011-01-22       Impact factor: 3.201

2.  Retinoic acid and α-galactosylceramide differentially regulate B cell activation in vitro and augment antibody production in vivo.

Authors:  Qiuyan Chen; Kara L Mosovsky; A Catharine Ross
Journal:  Clin Vaccine Immunol       Date:  2011-04-06

3.  Retinoic acid and α-galactosylceramide regulate the expression of costimulatory receptors and transcription factors responsible for B cell activation and differentiation.

Authors:  Qiuyan Chen; Kara L Mosovsky; A Catharine Ross
Journal:  Immunobiology       Date:  2013-05-20       Impact factor: 3.144

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.